| Name | Title | Contact Details |
|---|
PAE is a leading provider of enduring support for the essential missions of the U.S. government, its allied partners and international organizations. In its 60th year of business, PAE provides services in capacity building and stabilization, expeditionary logistics, critical infrastructure, aviation services, test and training ranges, identity and information management, and training solutions to support the complex missions of our customers around the world. Today, the approximately 15,000 members of our global workforce perform with excellence and dedication in over 50 countries, on all seven continents, in some of the world`s most challenging regions. We attribute our success to the quality of our work and the integrity and high ethical standards that define our business operations. PAE is headquartered in Arlington, Va.
Flamel Technologies SA is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently has approvals for and markets two previously Unapproved Marketed Drugs ("UMDs") in the USA, Bloxiverz® (neostigmine methylsulfate injection) and Vazculep® (phenylephrine hydrochloride injection). The Company intends to add to this branded business by creating additional products, focusing on the development of products utilizing Flamel`s proprietary drug delivery platforms, and recently announced FDA acceptance of its third NDA filing with an FDA-assigned PDUFA date of April 30, 2016. Flamel also has several products in development utilizing Micropump® (oral sustained release microparticles platform) along with its tangent technologies, LiquiTime® and Trigger Lock™. The lead project for Micropump® is sodium oxybate. LiquiTime® allows for the extended-release of liquid medicines (such as ibuprofen and guaifenesin) and Trigger Lock™ is an abuse-resistant iteration of Micropump®, designed specifically for long-acting opioids (such as hydromorphone). Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology currently being studied with exenatide. Flamel`s products are targeting high-value molecules and will utilize either the 505(b)(2) approval process for NDAs or biosimilar pathways ultimately approved by FDA and other regulatory authorities. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and Dublin, Ireland.
Healthier Moms and Babies is a non-profit organization in Allen County, Indiana, that provides programs, resources, and education to help low-income, pregnant women have the healthiest babies possible.
Talking Rocks Cavern is a Reeds Spring, MO-based company in the Consumer Services sector.
Northland Auto Body Inc is a Kansas City, MO-based company in the Consumer Services sector.